Mono-PEGylated thermostable Bacillus caldovelox arginase mutant (BCA-M-PEG20) induces apoptosis, autophagy, cell cycle arrest and growth inhibition in gastric cancer cells

[1]  Y. Leung,et al.  Arginine deprivation as a strategy for cancer therapy: An insight into drug design and drug combination. , 2021, Cancer letters.

[2]  Chang-song Wang,et al.  Significance of Detection of the HER2 Gene and PD-1/PD-L1 in Gastric Cancer , 2020, Journal of oncology.

[3]  Y. Leung,et al.  Recombinant Bacillus caldovelox Arginase Mutant (BCA-M) Induces Apoptosis, Autophagy, Cell Cycle Arrest and Growth Inhibition in Human Cervical Cancer Cells , 2020, International journal of molecular sciences.

[4]  Yu Wai Chen,et al.  Design of a structure-based fluorescent biosensor from bioengineered arginine deiminase for rapid determination of L-arginine. , 2020, International journal of biological macromolecules.

[5]  Yu Wai Chen,et al.  Mono-PEGylation of a Thermostable Arginine-Depleting Enzyme for the Treatment of Lung Cancer , 2020, International journal of molecular sciences.

[6]  Y. Leung,et al.  A bioengineered arginine-depleting enzyme as a long-lasting therapeutic agent against cancer , 2020, Applied Microbiology and Biotechnology.

[7]  M. El-Sibai,et al.  Human Recombinant Arginase I [HuArgI (Co)-PEG5000]-Induced Arginine Depletion Inhibits Colorectal Cancer Cell Migration and Invasion , 2019, International journal of molecular sciences.

[8]  M. Rugge,et al.  Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives , 2019, World journal of gastroenterology.

[9]  C. Hsueh,et al.  Targeted and novel therapy in advanced gastric cancer , 2019, Experimental Hematology & Oncology.

[10]  O. Lee,et al.  Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions , 2019, BMC Cancer.

[11]  M. El-Sibai,et al.  Cytotoxicity of [HuArgI (co)-PEG5000]-induced arginine deprivation to ovarian Cancer cells is autophagy dependent , 2019, Investigational New Drugs.

[12]  T. Crook,et al.  A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma , 2019, Clinical Cancer Research.

[13]  P. Cheng,et al.  Recombinant human arginase induces apoptosis through oxidative stress and cell cycle arrest in small cell lung cancer , 2018, Cancer science.

[14]  M. Blades,et al.  Sensitivity of Colorectal Cancer to Arginine Deprivation Therapy is Shaped by Differential Expression of Urea Cycle Enzymes , 2018, Scientific Reports.

[15]  Xiaodong Zhu,et al.  Efficacy prediction of targeted therapy for gastric cancer: The current status (Review). , 2018, Molecular medicine reports.

[16]  F. Izzo,et al.  Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  W. Hung,et al.  A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients , 2017, Scientific Reports.

[18]  G. Cook,et al.  Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Jiajun Fan,et al.  A novel and promising therapeutic approach for NSCLC: recombinant human arginase alone or combined with autophagy inhibitor , 2017, Cell Death and Disease.

[20]  Zhongyu Liu,et al.  The role of autophagy in the cytotoxicity induced by recombinant human arginase in laryngeal squamous cell carcinoma , 2015, Applied Microbiology and Biotechnology.

[21]  K. Kelly,et al.  Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors , 2015, Clinical Cancer Research.

[22]  Yubin Li,et al.  Recombinant human arginase induced caspase-dependent apoptosis and autophagy in non-Hodgkin's lymphoma cells , 2013, Cell Death and Disease.

[23]  J. Wolchok,et al.  Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma , 2013, Investigational New Drugs.

[24]  M. Wangpaichitr,et al.  Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase , 2012, British Journal of Cancer.

[25]  S. Curley,et al.  Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts. , 2011, Translational oncology.

[26]  D. Wheatley,et al.  Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis , 2011, Pigment cell & melanoma research.

[27]  F. Izzo,et al.  Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Y. Leung,et al.  Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. , 2007, Cancer research.

[29]  F. Izzo,et al.  Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Bomalaski,et al.  Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. , 2002, Cancer research.

[31]  J. Bomalaski,et al.  Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[32]  F. Zölzer,et al.  Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis , 2000, Leukemia.

[33]  K. Miyazaki,et al.  In vivo anti‐tumor activity of arginine deiminase purified from Mycoplasma arginini , 1992, International journal of cancer.